Research Article
The Performance of Immunocytochemistry Staining as Triaging Tests for High-Risk HPV-Positive Women: A 24-Month Prospective Study
Table 4
Risk and relative risk of CIN2+ for baseline hrHPV, cytology, p16/Ki-67, and p16/MCM2 staining within 24-months.
| | Screening tests at baseline | CIN2+ | 24 months risk for new CIN2+, % (95% CI) | RRN (95% CI) | | Cumulative cases within 24 months, NC | New cases at follow-up screening, NN |
| | HrHPV | Positive | 28 | 6 | 3.3 (1.5–7.0) | 10.0 (1.2–82.3) | | Negative | 1 | 1 | 0.3 (0.1–1.9) |
| | Cytology | ASC-US+ | 11 | 0 | 0.0 (0.0–8.6) | — | | NILM | 18 | 7 | 1.6 (0.8–3.2) |
| | p16/Ki-67 | Positive | 25 | 5 | 5.4 (2.3–12.0) | 10.5 (2.1–53.5) | | Negative | 4 | 2 | 0.5 (0.1–1.8) |
| | p16/MCM2 | Positive | 24 | 6 | 4.7 (2.2–9.8) | 16.6 (2.0–136.2) | | Negative | 5 | 1 | 0.3 (0.1–1.6) |
| | Cocktail staining | Positive | 26 | 6 | 3.9 (1.8–8.2) | 12.8 (1.6–105.2) | | Negative | 3 | 1 | 0.3 (0.05–1.7) |
| | hrHPV+ & cytology | Positive | 11 | 0 | 0.0 (0–5.0) | — | | Negative | 17 | 6 | 2.4 (1.1–5.0) |
| | hrHPV+& p16/Ki-67 | Positive | 25 | 5 | 4.1 (1.8–9.3) | 8.6 (1.01–72.4) | | Negative | 3 | 1 | 0.5 (0.1–2.7) |
| | hrHPV+ & p16/MCM2 | Positive | 23 | 5 | 2.6 (1.1–6.0) | 3.5 (0.4–30.0) | | Negative | 5 | 1 | 0.7 (0.1–4.1) |
| | hrHPV+ & cocktail | Positive | 25 | 5 | 2.5 (1.1–5.6) | 3.1 (0.4–26.0) | | Negative | 3 | 1 | 0.8 (0.1–4.4) |
|
|
Cocktail staining positive means that either the p16/Ki67 or p16/MCM2 positive. |
